DaVita Inc. (DVA) Earnings Call Transcript & Summary
August 6, 2024
Earnings Call Speaker Segments
Nic Eliason
executiveThanks for joining us for this second-quarter conference call, and we're grateful that you continue to follow our company. This is Nic Eliason speaking, Group Vice President of Investor Relations, and with me today are our CEO, Javier Rodriguez, and our CFO, Joel Ackerman. I want to point out that we might deliver forward-looking statements on this call as defined under the federal securities laws. Known and unknown risks and uncertainties apply to each of those statements, and those factors could make actual results differ materially from what the forward-looking statements describe. If you'd like more information about these risks and uncertainties, please see our second-quarter earnings press release along with our SEC filings, which include our latest annual report on Form 10-K, every subsequent quarterly report on Form 10-Q, and any other later filings we make with the SEC. The information we currently have forms the basis for our forward-looking statements, and we have no intention and take on no obligation to revise those statements, except where the law requires it. We'd also like to point out that certain non-GAAP financial measures will come up during this call. Our earnings press release, which was furnished to the SEC and can be found on our website, contains a reconciliation of those non-GAAP measures against the closest comparable GAAP financial measures. At this point I'll hand the call over to Javier Rodriguez.
Javier Rodriguez
executiveThanks, Nic, and I'm glad all of you could join us today. On behalf of every teammate providing lifesaving care to our patients, I'm honored to report that DaVita has delivered another strong quarter. We remain focused on bolstering our clinical strengths while also refining revenue, operations, and our cost structure. During my comments, I'll review our second-quarter performance, offer my perspective on the CMS 2025 proposal, and close with our outlook for the remainder of the year. But first, as is our custom, I'd like to begin with a clinical achievement. Every single day, as you're aware, tens of thousands of DaVita caregivers devote themselves to giving life to our patients. Within our interdisciplinary care teams, nurses hold a central place — they act as our patient's caregiver, a sounding board, and a familiar face seen more than 100 times per year. Sadly, during the pandemic, thousands of nurses walked away from the profession. Because of that, a critical nursing shortage now confronts the healthcare system. The programs and initiatives we've put in place to support the next generation of dialysis nurses make me proud. Three examples deserve mention. First, together with leading nursing universities, we're developing tailored nephrology specific nursing curriculum. Beyond that, we provide monetary support designed to eliminate obstacles that keep future nursing students from enrolling. Next, we created a hands-on clinical internship initiative that places students directly into DaVita Dialysis Centers for practical experience. We currently have 700 clinical interns this year, and over 2000 people have participated since the program began. Finally, we developed a nurse residency program intended to shepherd incoming nurses along the path from student to working registered nurse. Our goal is to assist hundreds of nurses enrolled in the program in building stronger confidence throughout their initial year on the job, which can result, among other benefits, in improved patient safety. We're thrilled to play a role in reducing some of the strain on nursing staff and helping to make sure care remains accessible. Turning to how we did in the second quarter, adjusted operating income reached $506 million, while adjusted earnings per share stood at $2.59. That performance came in above what we had anticipated for the quarter, largely because of better-than-expected patient care costs and ongoing momentum in revenue per treatment, or RPT. Working against those gains was volume growth that fell short of our forecast. The main culprits were unusually high mistreatments tied to spring storms, plus a smaller-than-anticipated census increase. On top of that, our second quarter adjusted figures reflected roughly $15 million in costs from closing centers. During earlier quarters, those kinds of expenses were left out of adjusted operating income, treated as non-GAAP adjustments. We're going to go deeper on that topic as today's call continues. Now, a bit more color on how RPT is growing, because it keeps driving our solid results and backs the bump we've made to 2024 guidance. RPT involves plenty of moving parts, but two main drivers stand out. The largest one, which is where we begin, is our continuing effort to improve how well we collect the money owed to us; given that this is a multiyear grind, I'd like to devote a little extra time to it. Managing the revenue side has become increasingly complex over the last few years. When we bill health plans and bring in what they owe, there are now more often fresh data and process demands involved. Among these hurdles are working through prior authorization, billing rules that differ from payer to payer, the many payer portals that exist online, and items that get billed separately. On top of that come more layers: the roster of participating health plans keeps expanding because Medicare Advantage and the exchanges are growing, and our patients are switching their coverage selections more often. So we've made a set of focused bets on technology and on our team members in order to bring things up to date and hold onto best-in-class abilities. Greater automation of routine work, a higher electronic claim submission rate, and more frequent verification of benefit insurance are what these investments target, along with other upgrades. As a result, our overall collection rate has gone up and we're able to collect on claims faster, which brings day sales outstanding down; having grown more comfortable and experienced with these capabilities over the last year, we think the gains will hold and carry forward through 2020 and after. Turning to the second piece: because inflation has run higher over the past several years, our negotiations with health plans produced somewhat bigger rate increases. Even with those increases, we still aren't recovering the entire effect of elevated inflation. Our history of innovation and of discipline in the cost structure continues, and that's how we work to close this gap. Those two elements together, plus ongoing gains in payer mix, lift our outlook for RPT growth this year; back in the first quarter, we told everyone we expected to finish at the high end of our 2.5% to 3% RPT growth range for 2024. Progress has kept coming, so our expectation for 2024 RPT growth now sits in a 3.5% to 4% range. While we're still on revenue, CMS put out its ESRD Proposed Rule not long ago, which would update the prospective payment system for 2025. The roughly 2.1% rate increase CMS expects was largely what we had assumed internally. With a new wage index entering the picture, the methodology has grown more intricate, and although we value CMS trying to innovate, the proposal doesn't go far enough in capturing the industry's true cost inflation. We'll send CMS our feedback, hoping the methodology gets better in the final rule and in future years. If nothing further is changed, the proposed rule would keep applying pressure to the system. Also in that proposed rule, CMS restated its plan to fold oral-only drugs into the bundle starting next year as scheduled, and it flagged favorable policy changes meant to smooth that transition. CMS's position has DaVita's support, and because of what we've learned with calcimedics, we're firmly convinced this will give more patients access to these drugs, since a large share of our patients lack Part D coverage. We recognize that some groups are urging Congress to push back the start date, citing worries about patient access and whether providers can practically meet the requirements. DaVita is fully ready and putting the required funding behind this shift to help our patients. Now for our outlook for the entire year. We're raising our 2024 adjusted operating income projection, but we're also incorporating a revised method for handling our center closure expenses. Previously, our guidance range was $1.875 billion to $1.975 billion; it is now $1.91 billion to $2.01 billion. That's a $35 million bump at the midpoint. The change reflects a $95 million improvement in expected operating performance, which is partly offset because we now include approximately $60 million in full-year center closure costs that we used to exclude from adjusted operating income as a non-GAAP adjustment. Joel will provide further detail on this change to how we present our non-GAAP reporting. This outlook reflects the continued momentum we're seeing across our major operating metrics — including the revenue per treatment gains we talked about earlier — along with what we expect to be a solid performance over the second half of the year. At this point, I'll pass it to Joel, who will walk through our financial results and guidance in more detail.
Joel Ackerman
executiveAppreciate that, Javier. For the second quarter, adjusted operating income came in at $506 million, adjusted EPS landed at $2.59, and free cash flow reached $654 million. Before getting into the details of how we performed this quarter, I want to expand a bit on the reporting presentation change for our non-GAAP results that Javier brought up. Following a recent common letter the SEC sent to DaVita, center closure costs will no longer be treated as an adjustment within our non-GAAP presentations. Those center closure costs hit our patient care cost line, our G&A line, and our depreciation and amortization expense line. Adjusted OI and adjusted EPS for Q2 now reflect center closure costs, and the updated full-year 2024 guidance we shared today applies that same methodology. To make comparisons against prior periods easier, we're now also presenting prior period results under the new methodology. Taken together, these costs come to about $15 million each quarter in 2024, amounting to roughly $60 million anticipated for the year; by way of comparison, center closure costs during 2023 totaled approximately $100 million. Looking at 2025, we're projecting $20 million to $30 million in center closure costs. None of these presentation changes affect how we run the business, nor do they affect our overall profitability, cash flow, or long-term expectations; with that said, let me walk through each component of our Q2 performance, beginning with U.S. dialysis and particularly treatment volume. On a sequential basis, treatments per day rose 1.1% in Q2 compared with Q1. That gain was mainly driven by census gains during the quarter along with a seasonal improvement in mistreatment rate. Measured against the same period a year ago, second quarter treatments per day increased 50 basis points.
Beryl
executiveNext, U.S. net census gains came in below what we had anticipated. Even though new-to-dialysis admissions increased across a sixth straight quarter, our mortality rate exceeded projections; we foresee both trends putting downward pressure on the back half of the year. Taking the year as a whole, our current outlook is for treatment volume growth somewhere in the range of 0.5% to 1%. Sequentially, revenue per treatment rose by roughly $6. That gain stems mainly from the usual seasonal pattern tied to greater patient coinsurance and deductibles during Q1. As Javier explained, for 2024 we now project full-year growth in revenue per treatment of 3.5% to 4%. Quarter-over-quarter, patient care costs per treatment stayed roughly level. The customary seasonal drop from things such as elevated payroll taxes in Q1 was offset by greater health benefit expenses and other inflationary increases during Q2. Versus Q1, depreciation and amortization fell $12 million in Q2, partly driven by lower center closure costs. Within D&A, center closure costs totaled about $50 million in 2023, versus $10 million in 2024. Because those costs now sit inside our adjusted D&A figures, we anticipate an adjusted D&A decline year-over-year of roughly $40 million to $50 million. Turning to Integrated Kidney Care, or IKC, our value-based care operation, operating income fell $8 million from the prior quarter. Consistent with past patterns, we anticipate significantly stronger results in the latter half of the year than in the first half, owing to the timing of revenue recognition. International operating income held steady quarter-over-quarter. Our acquisitions in Ecuador and Chile have closed, and we anticipate our Colombia acquisitions closing in Q3 and our Brazil ones by year-end. Shifting to capital structure, during the second quarter we bought back 2.7 million shares, and so far in Q3 we have repurchased another 1.1 million shares. At the close of Q2, leverage stood at 3.1 times EBITDA. That figure came down relative to three months earlier, thanks to trailing 12-month EBITDA growth and a net debt reduction exceeding $200 million. At the end of Q2, we held roughly $400 million in funding from Change Healthcare's parent, UnitedHealth Group, tied to the cyber event from earlier this year. As of today, that balance is approximately $300 million, and we anticipate further repayment in line with successful collections on affected claims. We keep collecting on Change Healthcare impacted claims, and U.S. dialysis days sales outstanding dropped 14 days quarter-over-quarter. As we always do, we are evaluating ways to optimize our capital structure, including looking at how to address what remains of our term loan B maturing in 2026. Our target remains leverage within the 3 to 3.5 times range. Toward that end, we are likewise assessing ways to raise our debt so we have adequate capacity to keep leverage inside that range. In closing, allow me to provide some further detail regarding our revised adjusted operating income and adjusted EPS guidance for 2024. Like Javier mentioned, our adjusted operating income outlook now spans $1.91 billion to $2.01 billion. A number of elements are shifting inside that figure, so allow me to walk through the main pluses and minuses. To start, expenses tied to shutting down centers are now part of this adjusted OI range. That adds roughly $60 million in operating costs that our earlier adjusted OI guidance had excluded. As I noted before, this reflects a presentation change for our adjusted results and has no effect on GAAP financials or cash flows. Next, roughly 50 to 100 basis points of extra RPT growth compared with what we previously anticipated works out to about $85 million more at the midpoint. Third, the range incorporates better-than-expected patient care costs, largely from labor and productivity gains, which is largely canceled out by our updated full-year volume assumptions. Taken together, these shifts add up to roughly $35 million of higher adjusted operating income guidance at the midpoint. We're also revising our 2024 adjusted earnings per share guidance to $9.25 to $10.05, mainly because adjusted OI has risen. That wraps up my prepared remarks. Operator, let's begin the Q&A.
Pito Chickering
analystHi there. Good afternoon, everyone. Strong quarter, and I appreciate you fielding the questions. Regarding the NAG, could you share some detail about what you observed during the quarter and what you observed in July? If you look at the top end of your updated guidance, you reach growth of roughly 1.5%, which represents a significant increase compared with what you experienced in the first half of the year; so I just want to understand what you're seeing that provides confidence in that high end.
Javier Rodriguez
executiveAbsolutely. Thanks, Pito. So during the quarter, what we truly observed was that mistreatments came in higher than we anticipated, and our census growth fell short of expectations. That pattern has persisted — new to dialysis admits stay robust, and the expansion there matches what we witnessed before COVID, while mortality continues to be elevated. As for the back half of the year, I'd highlight one factor that gives us confidence: we have an additional treatment day in the second half of the year compared with the second half of last year. That alone accounts for roughly 30 bps of extra growth. Beyond that, we truly haven't modeled in many changes for the back half of the year; we haven't incorporated much census growth, and we anticipate the mistreatment rate will remain challenging; so if you really consider the back half of the year, the year-over-year growth essentially comes down to treatment days rather than any shift in any of the underlying assumptions.
Pito Chickering
analystAll right, that's reasonable. You listed a number of the pieces, but when we take out the $60 million in closure costs, your guidance went up by $95 million. Could you walk us through what makes up that $95 million increase compared with the prior guidance? I'd simply like to grasp it as I'm thinking about 2025. Thanks.
Joel Ackerman
executiveCertainly. I'd begin with revenue per treatment, since we shifted the guide from what was basically 3% last quarter to now 3.5% to 4%. At the midpoint, 75 bps equals about $85 million. That's the first item. It stems from a mix of ongoing gains in revenue operations, the contracting strength we've experienced so far this year, and a modest favorable mix shift, so that's the biggest piece and accounts for $85 million. Also adding to it is some betterment in labor costs. Two points stand out there. First, certain premium pay items, such as overtime or spot bonuses, have declined. Second, we're getting somewhat stronger productivity this year than we had anticipated. Together those two items are roughly $30 million; and working against that is roughly $20 million of OI headwind tied to the lower volume we flagged. So $85 million added from RPT, $30 million added from labor, less $20 million from volume, which brings you to a $95 million increase prior to factoring in the $60 million shift in center closure cost.
Pito Chickering
analystGreat, thank you very much.
Justin Lake
analystThank you. I'd like to build on what Pito asked. You mentioned $20 million due to reduced volume?
Javier Rodriguez
executiveCorrect, Justin.
Justin Lake
analystAnd you reduced the volume figure by roughly 75 basis points at the midpoint, correct?
Javier Rodriguez
executiveThat's right. What I'd say is that when we were working through this, our internal models last quarter most likely didn't have us landing at the midpoint. So you would likely need to begin from a somewhat reduced volume figure in order to bridge your way to that $20 million.
Justin Lake
analystPerhaps that figure comes to 50 basis points. I'm simply attempting to work through how volume relates to OI in this comparison.
Javier Rodriguez
executiveCorrect, that range sounds about right.
Justin Lake
analystSo from where you sit, would 50 basis points of volume translate to roughly $20 million of OI across a full year?
Javier Rodriguez
executiveThat's right. If you'd come to me separately and said, what does 50 basis points of volume come to, I'd likely have said $50 million to $60 million, so perhaps go with a somewhat smaller figure.
Justin Lake
analystThat's a different matter entirely.
Javier Rodriguez
executiveOh, my apologies, my apologies. Let me correct myself — 1% equals 50 to 60, so your estimate is roughly on target.
Justin Lake
analystAll right. Then regarding the closing of centers, was the figure you mentioned 20 million dollars or 30 million dollars for the coming year?
Javier Rodriguez
executiveFor 2025, we believe it will fall within that range.
Justin Lake
analystAll right.
Javier Rodriguez
executiveLet me clarify one thing on that: in building out your model for center closure costs, you need to keep in mind that the full expense doesn't land the moment a clinic shuts its doors. Certain items — lease acceleration costs, to take one instance — may only show up some time after the clinic has closed. So my expectation is that by next year, the rate at which we close clinics ought to be right back at the pre-COVID level, roughly 20 clinics annually, in that vicinity. The costs we're flagging, though, will be a lingering effect of what we've already experienced. A portion of them will carry over from the clinic closures that happened in 2024.
Justin Lake
analystUnderstood. That's the point I was hoping to reach; so your expectation is that next year you'll return to something similar to the 2020 level of center closures?
Javier Rodriguez
executiveYeah, roughly that. For this year, I believe during the prior quarter we had indicated 50 for the full year. We're likely a bit under that. And my guess is that by the time the year ends, we'll have shut only around 40 across the year and be returning to a more typical rate next year.
Justin Lake
analystAlright. Then, before I sign off, just one thing on revenue for treatment. First, I believe you mentioned in the release that you had certain offsets to pricing stemming from mix pressure. How does mix in the second quarter compare with Q1?
Javier Rodriguez
executiveIn Q2, mix declined by a drop, though it's sitting at roughly 11%. That's essentially the same level as at the start of the year. When it came to our commercial mix at the close of Q1 — which I don't believe we disclosed — estimating it was somewhat tougher owing to certain changes, certain difficulties involving Change Healthcare, since some claims got delayed. Still, I don't think commercial mix moved much between Q1 and Q2 in any way that would carry a meaningful financial effect.
Justin Lake
analystAnd then finally, regarding the exchanges—so my understanding is you finished the year at 10.9, if I recall the fourth quarter report correctly; but let's just say you're at 11. What portion of that is currently coming from exchanges, and what portion came from exchanges, say, before COVID?
Javier Rodriguez
executiveYes, that figure has risen by roughly 200 basis points.
Justin Lake
analystAll right, that's mine to take. Much appreciated, everyone, and thanks.
Javier Rodriguez
executiveThanks.
AJ Rice
analystHello, and thank you for taking the question. Regarding the IKC business, my rough math for the year so far shows a loss of roughly $60 million. Your stated goal for this year is $50 million, and in the prepared remarks you mentioned expecting more favorable results in the latter half. Is $50 million still what you're targeting? And would that imply profitability in both Q3 and Q4?
Javier Rodriguez
executiveThanks for asking, AJ. Your figures are correct — we're sitting at negative $60 million and change on a year-to-date basis — and our expectation remains that the full year lands in that $50 million range. That isn't really driven by any major shift in the business, though; it's more about revenue recognition occurring later in the year, and that's the key distinction. And as you're aware, with this business we've encouraged you to evaluate it on an annual basis, since quarter-to-quarter swings can be somewhat more extreme, but the range still stands.
Joel Ackerman
executiveRight, and AJ, regarding that split across Q3 and Q4, predicting exactly when revenue shows up is difficult for us. Still, my expectation is that Q3 will again be a quarter with a loss, while Q4 will be a far, far stronger one. That said, some of the Q4 revenue might come earlier into Q3, depending on when the information reaches us.
AJ Rice
analystAlright, so it sounds like most of what you said about volume relates to the impact of the storm and the mistreatment, but you mentioned mortality too. How did mortality actually look? And was that a significant factor in your decision to adjust, or is this just the normal quarter-to-quarter variation you see?
Joel Ackerman
executiveCorrect. So briefly, mortality is definitely coming in higher than we had expected, and it might be useful to pause and walk you through how we think structurally about our volume position for the year; and from that perspective, the question we keep asking ourselves is that we're behind on volume growth, about 150 bps compared to pre-COVID versus the level we'd like to hit; and we've put a lot of work into measuring that. What we're able to do is limited by the data we have, covering both how good the data is and how current it is, recognizing that we're working with quite small numbers here, 100 bps, 150 bps, with inputs that carry a fair amount of volatility or variability. Even so, in our effort to measure it, we believe the $150 million gap between our volume growth for the year and what it was pre-COVID really breaks down into two parts. Somewhere between 50 bps and 100 bps of that gap comes from mortality. Mortality is just trending above its prior level. In fact, it's higher this year than it was six months ago; and we believe structurally that this is the biggest reason we aren't 150 basis points higher. The second piece, we think, is tied to the capital efficient strategy we adopted for running our clinic footprint. If you look back three or four years, volume across our business and the entire industry had begun to decline. We saw that our capacity utilization was falling, and we focused heavily on getting back to a healthy capacity utilization, one capable of supporting what we invest in our teams, in clinical quality and in information technology. What happened next was that we cut de novos ahead of others, and we closed approximately 200 clinics across the last few years. All of that led to a drop in our clinic share over the last few years, roughly a point and a quarter. And because of that, we believe some volume has been lost. Quantifying it is hard, but if a range were required, it would probably land somewhere between 40 and 60 basis points. So when you combine those two items, 50 to 100 basis points of mortality above the historical level, together with a 40 to 60 basis point effect from how we managed our clinics footprint, we think that explains most of the 150 basis point gap. One key point I want to flag: new dialysis admissions aren't included in the gap list we have. Like I've mentioned previously, those continue to look robust. The rise in new dialysis admissions is in line with the growth we saw prior to COVID, and it remains at a solid level. So ideally, right at the beginning, I covered your question regarding the year and then gave a bit more background on the larger picture. Javier, is there anything you want to add? By the way, roughly 1.25 of call it.
Javier Rodriguez
executiveYes, let me tack on a single point. To start with, right at the opening of his sentence, Joel accidentally came out with 150 million, and what he actually meant was 150 basis points — I just want that on the record. For the remainder of the call, he was consistent about the 150 basis points. That said, although he took you through plenty of figures, ultimately what you and the rest of us keep asking is whether some structural shift is going to alter the growth rate. Based on the work we've done, the best answer we can give is no. It looks like we're in what you might call a stretch of time in which mortality runs high, yet as we look through these patients who are new to dialysis, the volume ought to return to normal over time.
AJ Rice
analystOkay, great. Thanks so much.
Javier Rodriguez
executiveThank you.
Andrew Mok
analystThanks. To build on what was said regarding mortality, what is the underlying premise for why it is running high? During the initial pandemic period, the excess mortality pattern would logically point to a benefit later on. So what is the basis for your expectation that it stays elevated? Thank you.
Javier Rodriguez
executiveYeah. This is something we have discussed frequently and have engaged our physician community about, attempting to determine the cause. The truth is that hypotheses are proposed and one can partially substantiate them, a more severe flu season, and so forth. Yet the genuinely measurable explanation is not something we could state with certainty. Conversely, we are beginning to observe gains in areas that ought to affect mortality, such as integrated kidney care, upstream patient management, novel medications, SGLT2 and GLP-1, and so on; therefore we are puzzled and will continue investigating, and once we have something reliable, we will communicate it to you.
Andrew Mok
analystGreat. Okay, thank you. So in the prepared remarks, I believe you said that better collections represent a multiyear undertaking, and considering how much progress we've made across the last six quarters, where does that leave us currently, and how much room remains after 2024? Thanks.
Javier Rodriguez
executiveYes, I would say additional benefit will certainly show up in 2025, arising at minimum from annualizing the gains we anticipate in this year's back half. Beyond that, I think it's fair to assume that these advantages will diminish over time. In other words, their contribution to RPT growth will converge as time goes on. From where I sit, we can hold onto all the progress made so far. Even so, it's tough to forecast how much more upside remains or when we're likely to capture it. Compared with the situation a few years ago when we kicked this off—and when we initially walked the street through it in Q2 of 2022—I'd say it's reasonable to call the results well beyond our original expectations.
Andrew Mok
analystGot it. May I follow up on just one more thing? From what I understand, you said that closing clinics might also put pressure on volume growth. Since both you and one of your biggest competitors are shutting clinics at the same time, what level of patient leakage do you anticipate, and if those patients don't go to either of the two major dialysis chains, where would they receive dialysis care? Thank you.
Javier Rodriguez
executiveRight, we've invested a lot of work looking into this, and the interesting part is that our data at the clinic level is actually better. The information we have on clinic share is more robust than what we hold on treatment share; and we believe that mid-size and smaller dialysis operators have actually been picking up share over the last several years. They've closed fewer clinics, they've opened more of them, and because of that, they are probably picking up some volume. That said, we were at 7.9% to end the year.
Joel Ackerman
executiveNow, regarding that point, we pose the question to ourselves: does this benefit us or harm us? Naturally, your mind goes to market share in most cases, though here it concerns clinic share. Our perspective—and naturally, only time will reveal the answer—is that we took the lead in halting de novos when deaths were climbing throughout the pandemic. You saw DaVita's construction activity, which came to a very aggressive stop, and afterward we took the lead in properly aligning capacity. So to put it simply, you'd state that we shut down approximately 200 centers. Based on how you calculate it, you might say that's approximately $100 to $150 million in reduced fixed expenses; meanwhile, the volume we lost comes to about $50 million; therefore, purely from those figures, it appears we're choosing the correct trade off. Naturally, numerous other factors are at play—patient access, relationships with physicians locally, and every standard element we must factor in. However, I'm only presenting the financial aspect to you.
Andrew Mok
analystGreat. Thanks for all the color.
Javier Rodriguez
executiveSure. Hey, before we take the next question, I just want to return to something I said in response to Justin regarding the exchanges. I mentioned a 200 basis point increase from the exchanges. I just wanted to make clear that this refers to 200 basis points of revenue, not a 200 basis point mix increase that came from the exchanges. So I just wanted to make sure that was clear.
Kevin Fischbeck
analystThanks, that's helpful. To build on what was just discussed, could you provide the share of revenue generated by the exchanges for the year to date?
Javier Rodriguez
executiveSure — however, I doubt we'll be disclosing that figure, Kevin.
Kevin Fischbeck
analystThen during your prepared comments, you touched on leverage, and I believe you mentioned wanting to take on additional debt so that capacity would fall within a certain range. Is your point that you might increase borrowing in order to put more money to work, perhaps through buying back stock, or did you mean something different?
Javier Rodriguez
executiveRight, I'd steer clear of the term "lever up," since our actual aim is keeping the leverage range at three to 3.5 times. If we intended to push our leverage range, or our leverage multiple, beyond that level, then I'd call that levering up. The way I see it, as our EBITDA increases, to hold that three to 3.5 times leverage range — and remember, we currently sit at the low end of it — we require additional debt capacity, and you simply take the midpoint of that figure. When EBITDA rises, you multiply it by 3.25%, and that gives you the capacity required. So we're considering how much debt capacity is necessary to guarantee we remain within that range as EBITDA increases.
Kevin Fischbeck
analystAll right. And theoretically, that capacity would go toward buying back stock. Is that right, or are there other possibilities?
Javier Rodriguez
executiveWell, it would be deployed according to how we think about allocating capital; the top priority would be putting it into growth, with the understanding that such growth has to be efficient with capital and clear our return hurdles. If that doesn't pan out, repurchasing shares would definitely sit right at the top of the list for how we'd deploy surplus capacity to keep our leverage where it is.
Kevin Fischbeck
analystAll right, and on that same topic, regarding the line of credit change, what should we make of it? In fact, I suppose your free cash flow—would that be a use of free cash flow to repay it, or do you simply receive less from United?
Javier Rodriguez
executiveNo, I view it simply as debt, and it's part of our net debt figure as of today. If we drew an additional $400 million on the revolver, or completed a bond deal and applied the proceeds to reduce the change debt, that's merely one type of debt being swapped for another type of debt. Therefore, it wouldn't affect free cash flow. It wouldn't alter our leverage ratio.
Kevin Fischbeck
analystAll right. Then I suppose, turning back to that mortality issue, since it's tough to grasp why it has become such a problem at this point. And, well, I mean, it's difficult to say if the underlying causes aren't completely clear to you; it's difficult to say when things would return to normal. But have you given any consideration to why matters wouldn't revert to normal across the coming couple of quarters? And I suppose, what are you watching for in order to recognize that you've moved past it?
Joel Ackerman
executiveWell, making predictions isn't a wise approach, in my view, since the likelihood of getting it wrong is essentially 100%; but the fact is that we share your view that we don't believe it's structural and that it will go back to normality. And once more, I've pointed to several of the gains that we believe can come about from mortality; and a lot of people ask, well, why aren't you certain about exactly what occurred? And what's assumed is that death occurs while they are undergoing dialysis.
Kevin Fischbeck
analystAll right, perhaps only one more question. Given that treatment revenue appears to be a significant contributor to the increased guidance, it seems like you believe everything that has occurred thus far can be maintained. I suppose the next steps shift somewhat. Could you elaborate a bit further on commercial contracting? It sounds like that may have performed slightly better than you had anticipated. Regarding more effectively catching up with recent inflation, how should we consider commercial contracting in 2025? Will that continue to be a tailwind comparable to what you are currently experiencing, or will it settle down for some reason?
Joel Ackerman
executiveWell, regarding RPT, essentially there are three dynamics to consider. You have mix, you have negotiations, and you have revenue cycle, so your question concerns the negotiations. And I believe that to consider what lies ahead, you must sort of imagine yourself in the future, which means asking what the environment is? Is inflation still present, which contracts are due for negotiation, et cetera? As we have described previously, we are contracted comprehensively, and our major contracts typically renew every three to four years.
Kevin Fischbeck
analystUnderstood. Perhaps let me put the question another way. When you're picking up some commercial contracting, do you sense any change in how talks are going? Either managed care organizations see they require you more because of network considerations, or they value what you bring to the table to a greater degree, and that hands you more leverage at the bargaining table — or is it simply this: inflation has risen, so a rising tide lifts all boats.
Javier Rodriguez
executiveMy sense is that the discussions remain unchanged, in the sense that everyone is attempting to contribute their fair portion and keep costs down. Everyone is attempting to bring value to the patient community, maintain a broad network, and simply perform as well as possible. And naturally, we must factor in expenses and inflation along with all such matters, yet apart from taking inflation into account, those dynamics have stayed the same.
Kevin Fischbeck
analystGreat. Thanks.
Javier Rodriguez
executiveThank you.
Ryan Langston
analystHello, and good evening — thanks. I've got just two questions. Regarding the softer census growth, perhaps I missed this, but does it affect only certain regions, or are there particular areas that might be doing worse than roughly the typical level and perhaps dragging it down somewhat?
Javier Rodriguez
executiveNo, Ryan, what we're observing is basically uniform everywhere.
Ryan Langston
analystUnderstood. Then, only to make sure it's clear, perhaps regarding the RPT gain, it appears you clearly remain in the process of addressing that, and a portion of it is going to annualize during 2025. Would it be reasonable to think that could ultimately, purely on a year-over-year basis, land nearer to 3.5% to 4%? For this year you're providing guidance, in contrast to possibly the 2.5% to 3%?
Javier Rodriguez
executiveMy apologies, is your question concerning RPT for 2025?
Ryan Langston
analystYeah, what I'm trying to get at is whether your 3.5% to 4% target applies to this year, with a portion of that carrying over into the following year. Is it reasonable to expect the growth rate could be higher — nearer to 3.5% to 4% in 2025 compared with what we might have seen before? We had been thinking something more like 2.5% to 3%?
Javier Rodriguez
executiveYes. Guidance at this point is premature, but I wouldn't move to 3.5% to 4% for next year. Delivering at that level for one more year strikes me as quite a stretch.
Ryan Langston
analystOkay, thanks.
Javier Rodriguez
executiveThank you.
Pito Chickering
analystHi everyone, a few short follow-ups from my side. During this quarter, what share of your treatments took place at home, and what was your center liquidization for the quarter, and how does that stack up against the first quarter?
Javier Rodriguez
executiveSure, home utilization continues to sit in the mid to high 15s. As for capacity utilization, we're at roughly somewhere between 58.5 and 59, right around there.
Pito Chickering
analystAlright, then. Turning to the business outside the US, it looks like the margin is hovering near 7%, if I'm reading that right. What's your outlook for how that trends over the next two years?
Javier Rodriguez
executiveWhat I'd say is that expansion abroad during the next two years — and especially in the year ahead — is likely to land higher than our past track record, largely driven by the deal we closed in Latin America. And just to add some context there, we're somewhere between 58.5% and 59%.
Pito Chickering
analystApologies regarding the OI margins. We do like the track. It's roughly 7% <<inaudible>>, I'd say. How does that trend as time goes on?
Javier Rodriguez
executiveRight, my sense is that it will keep climbing gradually. Whether it could ever reach the U.S. margins, I don't have a view on that, though I'd call it highly unlikely.
Pito Chickering
analystAlright, final question, Frankie.
Joel Ackerman
executiveWhen you look at margins abroad, a few different forces are at play. First off, "international" isn't really one single thing. It's 12 to 13 different countries. Naturally, each one carries a different weight. In certain of those markets, there's just a single payer — the government — so you'll see stretches with no raise at all, followed by one big lump increase, which makes the pattern somewhat more irregular and makes the margin tougher to forecast.
Pito Chickering
analystThen, I suppose, if margin is trickier, why would that be a smarter way to deploy cash flow compared with buying back shares?
Joel Ackerman
executiveSure, we have confidence in the adjusted return, though your question is actually a separate one — namely, are margin gains showing up?
Pito Chickering
analystAlright, that's reasonable. Now, regarding the final item on IKC — you added roughly 3,000 lives. That happened during the prior quarter. Yet the medical expense for each life comes to approximately 50% of the prior quarter's average. So when you bring new patients into IKC, could you describe the kinds of patient characteristics they have compared with those you currently serve? Many thanks.
Javier Rodriguez
executiveSure. I'd exercise some caution regarding that medical cost per life figure. For many of the lives you mentioned, their medical expenses don't actually pass through our P&L. Only the snippet lives are the ones whose medical costs do pass through. So I likely wouldn't use that calculation.
Pito Chickering
analystOkay, that's reasonable. Appreciate it, everyone.
Javier Rodriguez
executiveThanks, Pito.
Javier Rodriguez
executiveAlright. Thanks, Michelle, and thanks to everyone for asking. In closing, DaVita delivered yet another robust quarter, which came about because of the money we've put in over the last few years toward assembling an excellent team, solid systems, and stronger abilities as we plan for what's next. While it's somewhat soon to provide guidance, we feel the fundamentals behind our margins can hold up; on that basis, we're eager about what lies ahead that we can accomplish for the good of our patients, partners, and teammates. We appreciate your ongoing attention to DaVita. And take care.
Operator
operatorAppreciation to everyone, and that brings today's conference call to an end. At this point, feel free to disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.